Drug intelligence / Profile preview

HCV cVLP vaccine

Development stage: Preclinical
Lead developer: AdaptVac
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The HCV cVLP vaccine is a preclinical-stage prophylactic vaccine candidate developed by AdaptVac for the prevention of Hepatitis C virus (HCV) infection. It utilizes AdaptVac's proprietary capsid virus-like particle (cVLP) technology, which involves the display of the HCV envelope protein E2 on the surface of a virus-like particle. This platform is designed to mimic the structure of a real virus to induce a potent and broad immune response, specifically targeting the E2 protein to prevent viral entry into host cells. The vaccine aims to provide a solution for the global burden of Hepatitis C, for which no approved vaccine currently exists.

Other names: Hepatitis C virus capsid virus-like particle vaccine

Targets

HCV E2 (Hepatitis C virus envelope glycoprotein E2)

Beyond the preview

Go deeper on HCV cVLP vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HCV cVLP vaccine.

Explore the full profile